Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TRC105 and Axitinib in Advanced RCC
NCT01806064Phase 2Terminated
- Sponsor
- TRACON Pharmaceuticals, Inc.
- Start
- Mar 2013
- Primary completion
- Dec 2018
- Modality
- Monoclonal Antibodies
- Countries
- 4
01
Overview
A Phase 2 trial of carotuximab in renal cell carcinoma (RCC), sponsored by TRACON Pharmaceuticals, Inc.. Started Mar 2013; status: terminated.
02
Drugs
carotuximab
03
Conditions
renal cell carcinoma (RCC)
Beyond the preview
Go deeper on NCT01806064.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01806064.